Refractory Sclerosing Mesenteritis When Tamoxifen or Prednisone Has Not Worked

Clinical Scenario

This protocol applies to patients with sclerosing mesenteritis in whom first-line anti-inflammatory disease-directed therapy has not produced the expected symptom improvement — with maximal response to first-line agents expected around 4–6 months. When that benchmark is not met, the disease is considered severe and refractory, warranting escalation.

Prior Treatment — Inadequate Response

First line did not achieve symptom response

First-line anti-inflammatory therapy may include the following agents (used alone or in combination):

Tamoxifen Prednisone Colchicine Azathioprine

Failure to achieve improvement or response of symptoms — particularly when maximal response to prednisone and tamoxifen has not occurred by approximately 4–6 months — defines the threshold for moving to the next treatment line.

Next-Line Approach (Partial Overview)

For severe, refractory sclerosing mesenteritis that has not responded to first-line therapy, second-line immunosuppressant agents are available — though the evidence base for this step remains limited.

The full protocol details which agents are considered, their specific roles, and how they are selected — available via the structured regimen below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.cgh.2024.12.025

Drugs with limited data include rituximab, thalidomide, cyclophosphamide, methotrexate, infliximab, and ustekinumab.

All of these agents have the potential for significant side effects, and thus are typically reserved as second-line therapies for severe, refractory disease.

View source ↗